LCLissette Raquel Chang

Lissette Raquel Chang

*This is an algorithmically generated author record based on publicly available information.

Lissette Raquel Chang has a total of 13 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Strengthening Panama’s HIV Viral Load Testing Network through a Phased Optimization Strategy: A Retrospective Program Assessment, 2021-2025

    by Sandra I. Juarez, Andrés Azmitia Rugg, Cristine Gutierrez, Lissette Chang, David Cortes, Rolando Lorenzana, Carlos Vargas, B. Ryan Phelps, Ravikiran Bhairavabhotla

    Background: In 2021, Panama identified structural and operational gaps in its national HIV viral load (HIV VL) testing network, in the context of low testing coverage. A phased strategy was implemented to strengthen testing capacity, quality, geographic access, and referral pathways. Setting: Panama’s national HIV VL testing network. Methods: We conducted a retrospective program assessment of the national HIV VL network optimization strategy implemented from 2021–2025. A 2021 baseline assessment included two HIV VL reference laboratories and 13 antiretroviral therapy (ART) clinics representing 93% of the ART cohort reported in the programmatic data used for the assessment. Findings informed phased optimization, including redistribution of testing, establishment of regional capacity, and differentiated use of GeneXpert for priority HIV VL testing. Programmatic data were used to assess HIV VL coverage, viral suppression, testing distribution, and turnaround time. Results: HIV VL testing increased from 6,967 tests in 2021 to 15,897 in 2025, while the ART cohort increased 25%, from 14,560 to 18,200. HIV VL coverage increased from 47% to 89%, and viral suppression from 78% to 94%. Testing was redistributed across the laboratory network. Post-optimization routine turnaround time was approximately 1 week at the regional Veraguas laboratory and 10 days at ICGES; priority GeneXpert testing provided results in approximately 24 hours. Conclusion: Panama’s phased optimization was associated with expanded HIV VL testing access, increased coverage, redistributed testing capacity, and more timely testing pathways. These findings represent programmatic trends and should not be interpreted as causal effects of the strategy.

  • Open Access

    Analysis of Adolescent HIV Care Cascade Outcomes in PEPFAR-Supported Programs in Central America, October 2020–September 2024

    by Lissette Raquel Chang, Cristine Gutierrez, Jose Rodas, Nancy Aitcheson, Nasim Farach, Carlos Castaneda, Andres Azmitia Rugg, Benjamin Ryan Phelps

    To better understand recent adolescent (10–19 years) HIV trends in Central America, we analyzed routine data from countries supported by the United States President’s Emergency Plan for AIDS Relief (PEPFAR): Guatemala, El Salvador, Honduras, Panama, and Nicaragua, over the period from October 2020 to September 2024. Key PEPFAR indicators included HIV testing, HIV positivity rates, new treatment initiations, advanced HIV disease (AHD) at diagnosis, viral load coverage (VLC), viral load suppression (VLS), and multi-month dispensing (MMD) uptake for children and adolescents living with HIV (CALHIV) from 10–19 years of age. Since October 2020, the number of HIV tests conducted among adolescents has increased; however, the positivity rate has remained stable at approximately 2%. The number of adolescents initiating treatment increased by 21%. At the same time, VLS has shown steady regional improvement (from 73% to 90%), though VLC is a persistent challenge (80%). Treatment interruption rates have been relatively stable, fluctuating between 2% and 3%. Advanced HIV is high in adolescents new to treatment (34%), especially among females (40%), though cluster of differentiation 4 (CD4) testing at diagnosis has only been collected recently and coverage is not complete. The high prevalence of AHD among adolescents underscores the need to reinforce earlier and more targeted interventions for adolescents, especially in countries with greater HIV prevalence such as Panama and Guatemala.